Switching Between Wegovy and Zepbound Has No Official Dose Conversion, and One Model Pairs Semaglutide 2.4 mg With Tirzepatide 10 mg
People move between semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) over coverage, price, and side effects. Neither label explains how, and the studies on dose matching are small or indirect.
Key points
- Neither the Wegovy nor the Zepbound label explains how to switch from the other drug; both start low (0.25 mg and 2.5 mg) and raise the dose every 4 weeks to limit stomach side effects
- In SURMOUNT-5 (751 adults with obesity, 72 weeks), top tolerated doses of tirzepatide cut weight 20.2% versus 13.7% for semaglutide
- A 2026 model of diabetes trials estimated a 99.4% probability that semaglutide 2.4 mg and tirzepatide 10 mg give weight loss within 2 percentage points, and 94.8% for semaglutide 7.2 mg and tirzepatide 15 mg; two of three authors work for Novo Nordisk
- An October 2026 Israeli expert framework argues against always restarting at the lowest dose and suggests matched dose bands adjusted every 4 to 8 weeks, but says switching trials are still needed
- After a U.K. tirzepatide price rise of up to 170% in September 2025, switches from tirzepatide to semaglutide at one large online provider rose about 9 percentage points above trend
- A case report tied a switch from semaglutide to tirzepatide to lithium toxicity, and Zepbound's label calls for backup birth control for 4 weeks after starting
Why people switch
Semaglutide is sold as Wegovy for weight loss and Ozempic for type 2 diabetes. Tirzepatide is sold as Zepbound for weight loss and Mounjaro for diabetes. Both are weekly injections that act on the GLP-1 receptor, which helps control appetite and blood sugar, and tirzepatide also acts on a second receptor called GIP, so many people who start on one end up moving to the other.
Coverage is one reason. In WTW's 2026 survey of U.S. employers, the share covering GLP-1 drugs for weight loss fell from 57% to 53%, the first drop in three years, and 30% of employers still covering them said they were considering dropping coverage. A plan that drops one drug, or that covers only the other one, can push a patient to switch even when the first drug was working. Our employer coverage guide covers the options.
Price is another. When the U.K. list price of tirzepatide rose by up to 170% in September 2025, a study of more than 1 million self-paying adults at one U.K. online provider found that switches from tirzepatide to semaglutide rose by about 9 percentage points, then eased. Side effects, a weight plateau, and trouble finding a pharmacy that stocks the right dose also lead people to switch.
Switching is common in some places and rare in others. In a large private health network in Poland, 29.7% of patients with more than one GLP-1 prescription switched drugs at least once between 2018 and 2025. At a U.S. academic medical center, by contrast, most of 9,189 adults without diabetes who started semaglutide or tirzepatide simply stopped, and switching to another drug was rare.
What the labels say, and what they leave out
The FDA prescribing information, often called the label, sets out how to start each drug, but neither label explains how to move a patient from the other drug.
- Wegovy injection starts at 0.25 mg once a week and steps up every 4 weeks (0.5 mg, 1 mg, 1.7 mg) to a usual maintenance dose of 2.4 mg. The label now allows up to 7.2 mg for weight loss in adults who have tolerated 2.4 mg for at least 4 weeks.
- Zepbound starts at 2.5 mg once a week for 4 weeks. The 2.5 mg dose is only for getting started. The dose then rises in 2.5 mg steps, at least 4 weeks apart, to a maintenance dose of 5 mg, 10 mg, or 15 mg.
- Both labels say not to use the drug together with any other GLP-1 drug.
Both labels give the same reason for raising the dose slowly, which is to lower the risk of nausea, vomiting, diarrhea, and other stomach side effects.
The labels also cover gaps in treatment, which matter during a switch. Wegovy's label says that if 2 or more doses in a row are missed, dose escalation should restart at a lower dose. Zepbound's label says a missed dose can be taken within 4 days, and that after 4 days it should be skipped and the usual schedule resumed, but it does not address longer gaps. Our dosing schedule guide walks through each step and the missed-dose rules in more detail.
The Wegovy label also shows what a conversion looks like when a company has studied one. Novo Nordisk gives a direct swap between its own products: a person on Wegovy 2.4 mg injection can start Wegovy 25 mg tablets one week after the last shot. No label offers a comparable swap between semaglutide and tirzepatide.
How the two drugs compare dose for dose
The best direct evidence is SURMOUNT-5, a 72-week trial of 751 adults with obesity but without diabetes, published in the New England Journal of Medicine in 2025. People took the highest dose they could tolerate of either tirzepatide (10 or 15 mg) or semaglutide (1.7 or 2.4 mg). Weight fell 20.2% on tirzepatide and 13.7% on semaglutide. The trial was open-label, meaning participants knew which drug they got, and Lilly paid for it. Our head-to-head analysis covers the wider evidence.
That result compares top doses. It does not say which dose of one drug matches a given dose of the other. A 2026 model-based study in Diabetes Therapy tried to answer that for people with type 2 diabetes. The authors pooled results from 48 treatment groups (16,524 participants) in the main semaglutide and tirzepatide diabetes trials and asked which doses produced weight loss within 2 percentage points of each other. They estimated a 99.4% probability that semaglutide 2.4 mg and tirzepatide 10 mg were equivalent by that standard, and a 94.8% probability for semaglutide 7.2 mg and tirzepatide 15 mg. Lower semaglutide doses did not match the higher tirzepatide doses.
That model has limits. It used group averages rather than individual patients, it covered only people with diabetes, and two of its three authors work for Novo Nordisk, which makes semaglutide. It also predicts average weight loss, not how a given person will feel on the first dose of a new drug.
A new expert framework
On October 29, 2026, a group of Israeli pharmacists and endocrinologists from Ben-Gurion University, the health plans Clalit and Maccabi, and Rabin Medical Center published a proposed framework for switching in Expert Opinion on Pharmacotherapy.
According to the published abstract, the authors reviewed trials and cohort studies through May 2026 covering semaglutide doses from 0.25 mg to 7.2 mg and tirzepatide doses from 2.5 mg to 15 mg. They found no guidelines for switching. They used indirect comparisons to propose approximate dose bands of similar effect, along with a 5-step decision process.
Their main argument is that always restarting the new drug at its lowest dose can open a "therapeutic gap," a stretch of weeks on a weak dose during which weight can come back. Instead, they suggest estimating a matched dose and then adjusting every 4 to 8 weeks based on side effects and results. They say prospective trials, in which patients are switched on purpose and followed, are still needed to confirm exact conversions.
The full paper is behind a paywall, and we could not read its dose bands, so we have not reported them. The abstract is a consensus opinion built from indirect comparisons, not a trial result.
What happened when people switched
Studies that follow actual switchers are small.
- 15 patients in Japan. A 2025 study in Endocrinology and Metabolism followed 15 adults with type 2 diabetes who moved from semaglutide 1.0 mg to tirzepatide because they had lost less than 3% of their weight. All restarted tirzepatide at 2.5 mg and stepped up every 4 weeks, reaching 7.5 mg (10 patients) or 10 mg (5 patients). No stomach side effects were reported, which the authors linked to the patients already tolerating semaglutide. In the 10 mg group, HbA1c (a 3-month blood sugar measure) fell 0.7 points; weight fell 6.6 kg on average, but that change was not statistically significant.
- One patient who did better on semaglutide. A 2026 case report described a 40-year-old man who lost less than 5% of his weight on tirzepatide 15 mg over 6 months, then lost 20% over 6 months on semaglutide 2.4 mg. A single case cannot show how often this happens, but it is a reminder that the drug that works better on average is not always the better drug for each person.
- The U.K. price-change study. In the same large U.K. cohort, estimated 12-month weight loss was 19.9% among people on tirzepatide and 16.4% among people on semaglutide. Those figures describe everyone on each drug, not switchers specifically, and only some patients had follow-up weights.
Starting low versus matching the dose
A prescriber choosing a starting dose after a switch weighs two risks.
The first is stomach side effects. In SURMOUNT-5, the most common side effects on both drugs were stomach-related, mostly mild to moderate, and mostly during the weeks when doses were rising. That is why both labels start low, and why Wegovy's label calls for restarting at a lower dose after 2 or more missed weeks. Our nausea guide explains what helps.
The second is weight regain while on a weak dose. In trials where people stopped treatment entirely, weight came back: about 6.9% over 48 weeks after semaglutide was replaced with placebo in STEP 4, and about 14.0% over 52 weeks after tirzepatide was replaced with placebo in SURMOUNT-4, according to a 2026 systematic review. Those trials studied full stops, not short gaps during a switch, so they show the direction of the risk rather than its size during a switch.
No trial has randomly assigned switchers to a low restart or a matched dose, so the choice remains a judgment call. Dose decisions belong to the prescriber, who can weigh how well the first drug was tolerated, how long the break between drugs was, and the person's other medicines.
Other medicines can shift after a switch
Both drugs slow how fast the stomach empties, which can change how pills taken by mouth are absorbed.
Zepbound's label tells people who use birth control pills to switch to a non-oral method, or add a barrier method, for 4 weeks after starting Zepbound and for 4 weeks after each dose increase. That advice applies to anyone starting Zepbound, including people coming from semaglutide.
A 2026 case report in the Mental Health Clinician described a 23-year-old man taking lithium whose blood level rose from 0.9 to 1.7 mEq/L, with symptoms of lithium toxicity, after he moved from semaglutide to tirzepatide. His symptoms started 4 days after the first tirzepatide dose. IV fluids and a lower lithium dose resolved it. The authors judged the interaction probable but noted that no drug-interaction studies have tested it. Zepbound's label also flags drugs with a narrow safe range, such as warfarin. People taking lithium, warfarin, or similar drugs should tell their prescriber before switching.
Compounded semaglutide and tirzepatide are not FDA-approved, so the label schedules and trial results above describe the brand-name products, not compounded versions.
Questions for your prescriber
If a switch is on the table, these questions can help:
- Why switch now: coverage, cost, side effects, or a plateau? Would a dose change on my current drug do the same job?
- What dose of the new drug will I start on, and why? How fast will it go up?
- How long a gap will there be between my last dose of the old drug and my first dose of the new one?
- What should I do if nausea or vomiting is worse than before?
- Do any of my other medicines, including birth control pills, lithium, or blood thinners, need monitoring or a backup plan?
- If my insurance changes again next year, what is the plan?
People moving to retatrutide rather than between these two drugs can read our separate guide on that transition.
Limitations
- No randomized trial has tested how to switch between semaglutide and tirzepatide or compared a low restart with a matched dose
- We could not read the full Expert Opinion on Pharmacotherapy paper, so its specific dose bands are not reported here
- The dose-equivalence model used group-level data from type 2 diabetes trials and may not apply to people without diabetes
- The Japanese switching study had 15 patients, all with type 2 diabetes, followed for about 3 months
- The weight-regain figures come from trials in which people stopped treatment entirely, not from short gaps during a switch
- Switching patterns from Poland, the U.K., and one U.S. center may not reflect other health systems
Citations
- 1. Dose-Response and Clinical Equivalence of Semaglutide and Tirzepatide for Weight Loss in Type 2 Diabetes: A Model-Based AnalysisMeta-Analysis Diabetes Therapy 2026
- 2. Weight Regain After Discontinuation of GLP-1 and GIP/GLP-1 Receptor Agonists: A Systematic ReviewSystematic Review Metabolites 2026
- 3. Tirzepatide as Compared with Semaglutide for the Treatment of ObesityRandomized Controlled Trial New England Journal of Medicine 2025
- 4. Switching between semaglutide and tirzepatide in obesity Management: an expert-consensus framework for approximate clinical Efficacy-matched switching dosesReview Expert Opinion on Pharmacotherapy 2026
- 5. Early Dose Escalation of Tirzepatide after Switching from Semaglutide in Type 2 Diabetes MellitusOriginal Research Endocrinology and Metabolism 2025
- 6. Tirzepatide non-response with subsequent semaglutide response in class 2 obesityCase Report JCEM Case Reports 2026
- 7. Real-World Treatment Patterns and Weight Outcomes Before and After a Tirzepatide Price Increase in Over One Million Self-Paying UK Adults With Overweight or ObesityOriginal Research Diabetes, Obesity and Metabolism 2026
- 8. Switching patterns of GLP-1 receptor agonists from 2018 to 2025 in the largest private healthcare network in PolandOriginal Research Acta Diabetologica 2026
- 9. Patterns of Prescription Discontinuation, Reinitiation, and Switching of Subcutaneous Semaglutide and Tirzepatide in Adults With ObesityOriginal Research Diabetes, Obesity, and Cardiometabolism CARE 2026
- 10. Lithium toxicity following a change from semaglutide to tirzepatide for weight loss managementCase Report Mental Health Clinician 2026
- 11.
- 12.
- 13.
Peptides in this article
Full peptide profiles with evidence levels, dosing data, and safety notes live on peptidelist.org.
Related insights
Thanksgiving on Ozempic, Wegovy, Mounjaro or Zepbound: Big Meals, Alcohol, Nausea and When to Get Help
What the Wegovy, Ozempic, Zepbound, Mounjaro and Foundayo labels say about nausea, missed doses and warning signs, and dietitians' advice on plates and drinks.
How Ozempic, Wegovy and Mounjaro Change the Grocery Bill: 5% Less in Six Months in the US, £389 a Year Less in Britain
US and UK data show GLP-1 users' households buying fewer snacks and less fast food, then partly rebounding. The savings are small next to the drug bill.
Buying Wegovy or Mounjaro Abroad: Price Gaps, Import Rules, Counterfeits and Cold Storage
South Korea now lets travelers bring home three months of weight-loss drugs, then cracked down on resale. Rules elsewhere, storage limits and fake pens.